Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tolerability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,030 result(s) found for: Tolerability. Displaying page 7 of 702.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2004-000913-21 Sponsor Protocol Number: D1444C00147 Start Date*: 2004-10-05
    Sponsor Name:AstraZeneca R&D Södertälje
    Full Title: A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL) in P...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) HU (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000566-12 Sponsor Protocol Number: SA-NXY-0012 Start Date*: 2005-01-25
    Sponsor Name:AstraZeneca AB
    Full Title: CHANT (Cerebral Hemorrhage And NXY Treatment) A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase IIb study to assess the safety and tolerability of 72 hours intraven...
    Medical condition: Acute intracerebral hemorrhage not caused by trauma or tumor or being secondary to acute ischemic stroke, i.e hemorrhagic transformation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021814-43 Sponsor Protocol Number: 5703433 Start Date*: 2011-05-17
    Sponsor Name:Ulrich Tacke
    Full Title: The Safety and Tolerability of Methadone/Naloxone Combination in Opioid Substitution Treatment
    Medical condition: Patients with opioid addiction.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10030900 Opium addiction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000727-42 Sponsor Protocol Number: CYT004-MelQbG10 01 Start Date*: 2006-01-20
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A-VLP Vaccine in HLA-A2 Positive Patients with stage III/IV Malignant Melanoma
    Medical condition: Patients with Stage III/IV Malignant Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003798-94 Sponsor Protocol Number: ASM981A2308 Start Date*: 2004-12-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label, parallel-group study to investigate blood concentrations, safety and tolerability of 2 ointment formulations of ASM981 in adult patients with atopic dermatitis treated top...
    Medical condition: Atopic dermatitis (atopic eczema)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004686-13 Sponsor Protocol Number: LAS-212 Start Date*: 2020-05-01
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement o...
    Medical condition: Replacement of multiple coagulation factors in pediatric patients with acquired deficiencies due to liver disease and/or in pediatric patients requiring cardiac surgery or liver transplantation
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004945-10 Sponsor Protocol Number: E2007-J000-341 Start Date*: 2017-08-30
    Sponsor Name:Eisai Co., ltd
    Full Title: An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects
    Medical condition: Epilepsy
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000327-27 Sponsor Protocol Number: ISIS396443-CS2 Start Date*: 2017-01-26
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-005065-47 Sponsor Protocol Number: TM-105 Start Date*: 2018-05-15
    Sponsor Name:TikoMed AB
    Full Title: A single-centre, open single-arm study where the safety, tolerability and efficacy of subcutaneously administered ILB will be evaluated in patients with Amyotrophic Lateral Sclerosis
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004820-69 Sponsor Protocol Number: CSLCT-FLU-04-05 Start Date*: 2016-08-05
    Sponsor Name:CSL Limited
    Full Title: An Open-Label, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of CSL's Influenza Vaccine in a Paediatric Population (= or >6 Months to < 9 Years of Age).
    Medical condition: Influenza, human
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005905-51 Sponsor Protocol Number: W0003-01 Start Date*: 2006-02-20
    Sponsor Name:Stiefel Laboratories (Maidenhead) Limited trading as Stiefel International Research and Development
    Full Title: A PHASE II, SINGLE CENTRE, RANDOMISED, PARALLEL GROUP, CLINICAL STUDY TO INVESTIGATE THE TOLERABILITY OF DOUBLE BLIND CICLOPIROX NAIL PRODUCT COMPARED TO DOUBLE BLIND PLACEBO NAIL PRODUCT COMPARED ...
    Medical condition: Mild to moderate onychomycosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001711-67 Sponsor Protocol Number: VX18-659-106 Start Date*: 2019-08-21
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-659/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-003519-33 Sponsor Protocol Number: D1443L00003 Start Date*: 2007-01-25
    Sponsor Name:AstraZeneca UK Limited
    Full Title: RAPID - An Open-Label, Randomised, Multicentre Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immedicate Release), over 14 days, in Acute Schizophrenia / Schizoaffecti...
    Medical condition: Acute Schizophrenia and Schizoaffective Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004201-26 Sponsor Protocol Number: NC200602 Start Date*: 2007-03-15
    Sponsor Name:Neuro-Consil GmbH
    Full Title: Efficacy and tolerability of flexible dose adjusted pregabalin as first-line add-on treatment of patients with focal seizures
    Medical condition: epilepsis with seizures of focal origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003063-64 Sponsor Protocol Number: 3005031 Start Date*: 2018-10-05
    Sponsor Name:Orion Corporation, Orion Pharma
    Full Title: Open clinical trial to evaluate safety, tolerability, and efficacy of Dexdor for sedation in paediatric patients in intensive care settings. Multi-centre trial in Russia for marketing registratio...
    Medical condition: male and female patients aged 12 to 17 years with spontaneous or artificial ventilation and clinical need for prolonged (>24h) light to moderate sedation.
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-003861-17 Sponsor Protocol Number: AB0803 Start Date*: 2008-08-18
    Sponsor Name:Artu Biologicals Europe B.V.
    Full Title: A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinocon...
    Medical condition: Allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020057-13 Sponsor Protocol Number: 034-002 Start Date*: 2010-06-11
    Sponsor Name:Dermatologikum Hamburg
    Full Title: Proof-of-concept-study to Evaluate the Efficacy and Tolerability of Repeated Versus Single Treatment with Botulinum-Toxin (Vistabel®) Treatment in Combination with a Hyaluronic Acid (Juvederm-Ultra...
    Medical condition: moderate to severe glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052609 Glabellar frown lines LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023512-13 Sponsor Protocol Number: CAIN457A2302 Start Date*: 2011-05-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability and lo...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) IS (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005001-20 Sponsor Protocol Number: HIVECR Start Date*: 2015-05-21
    Sponsor Name:DR. ALEJANDRO SOUSA ESCANDÓN
    Full Title: CHEMO-RESECTION WITH HYPERTHERMIC INTRAVESICAL INSTILLATION (HIVEC-R) VS STANDARD TREATMENT IN PATIENTS WITH NMIBT: COMPARATIVE, PROSPECTIVE AND RANDOMIZED STUDY OF EFFICACY AND TOLERABILITY
    Medical condition: NMIBT
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000175-86 Sponsor Protocol Number: CN138-180 Start Date*: 2017-04-07
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization,
    Full Title: A 52-Week, Open-label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder
    Medical condition: Autistic disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 09:54:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA